GET THE APP

Safety and Efficacy of Ribociclib after Palbociclib in Patients with Metastatic Breast Cancer and Intolerable Toxicity | SciTechnol

Clinical Oncology: Case Reports.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Clin Oncol Case Rep Vol: 4 Issue: 1

Safety and Efficacy of Ribociclib after Palbociclib in Patients with Metastatic Breast Cancer and Intolerable Toxicity

Hiba H Moukadem* and Nagi S El Saghir

Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

*Corresponding Author:
Hiba H Moukadem
Division of Hematology-Oncology
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon
E-mail: hm127@aub.edu.lb

Received: September 14, 2020 Accepted: December 25, 2020 Published: January 25, 2021

Citation: Moukadem HH, Saghir NSE (2021) Safety and Efficacy of Ribociclib after Palbociclib in Patients with Metastatic Breast Cancer and Intolerable Toxicity. Clin Oncol Case Rep 4:1

Abstract

We present in this report two cases of hormone-receptor positive and HER-2/neu negative metastatic breast cancer treated in the first line setting with combination endocrine therapy and palbociclib. Case number one is that of a pre-menopausal woman who received luteinizing hormone-releasing hormone LHRH-analog (goserelin), fulvestrant and palbociclib and developed grade 3 oropharyngeal mucositis requiring interruption, dose reduction and discontinuation of palbociclib. Case number two is that of a post-menopausal woman who developed severe skin rash after treatment with anastrozole and palbociclib in whom the rash disappeared upon stopping palbociclib. Both patients developed intolerable toxicity that ended with discontinuation of palbociclib and were shifted to hormonal therapy plus ribociclib, with which those side effects did not recur. Both patients continued to have a good response to hormonal therapy plus ribociclib. We conclude from our report that cyclin-dependent kinase (CDK) 4/6 inhibitors palbociclib and ribociclib, apart from their known common toxicities such as neutropenia, have different toxicity profiles and can be safely exchanged in case of mucositis or skin rash and remain beneficial.

Keywords: Hormone receptor; Breast cancer; Therapy; Ribociclib

Track Your Manuscript

Google scholar citation report